

**510(k) Summary****1. Submitter's Name and Address:**

Edwards Lifesciences LLC  
One Edwards Way  
Irvine, CA 92614

**2. Contact:**

Kevin Drisko  
Sr. Regulatory Manager  
Edwards Lifesciences LLC  
One Edwards Way  
Irvine, CA 92614  
Phone: 949-250-2416  
FAX: 949-250-2303  
E-Mail: kevin\_drisko@edwards.com

**3. Date Prepared:**

February 23, 2006

**4. Device Trade Name:**

LifeStent FlexStar XL Biliary Stent System

**5. Device Common Name:**

Biliary Stent

**6. Device Classification Name:**

Biliary Catheter (78 FGE), Class II

**7. Predicate Devices:**

LifeStent FlexStar Self-Expanding Biliary Stent System (K053404)  
ev3 Protégé GPS Self-Expanding Nitinol Stent (K042204)



## 510(k) Summary (continued)

### 8. Device Description:

The LifeStent FlexStar XL Biliary Stent System consists of a self-expanding stent that is provided loaded into an over-the-wire catheter that acts as a delivery system. The stent is a permanently implanted device used to maintain patency of a major bile duct obstructed by tissue of an impinging tumor. The flexible, self-expanding stent is made by laser cutting an open lattice design into a nitinol tube. The subject device is supplied in lengths of 100mm, 120mm and 150mm and diameters of 6mm and 7mm.

### 9. Intended Use:

The LifeStent FlexStar XL Biliary Stent System is indicated for use in the palliation of malignant strictures (neoplasms) in the biliary tree.

### 10. Technological Characteristics:

Comparisons of the subject and predicate devices show that the technical characteristics such as materials, performance properties, biocompatibility, method of sterilization, and packaging are identical or substantially equivalent.

### 11. Performance Data:

Edwards Lifesciences completed bench testing such as deployment testing, dimensional testing, as well as tensile strength testing on applicable joints of the delivery system. The results indicate that the system performed in a manner substantially equivalent to the predicate devices cited in item 7 above.

### 12. Conclusion:

Since the LifeStent FlexStar XL Biliary Stent System has the same intended use, similar materials, similar performance properties, packaging and sterilization methods, it may be considered substantially equivalent to the predicate device cited in item 7 above.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAR 23 2006

Mr. Kevin Drisko  
Senior Manager, Regulatory Affairs  
Edwards Lifesciences LLC  
One Edwards Way  
IRVINE CA 92614

Re: K060487  
Trade/Device Name: LifeStent FlexStar XL Biliary Stent System  
Regulation Number: 21 CFR §876.5010  
Regulation Name: Biliary catheter and accessories  
Regulatory Class: II  
Product Code: FGE  
Dated: February 23, 2006  
Received: February 24, 2006

Dear Mr. Drisko:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:

The safety and effectiveness of this device for use in the vascular system have not been established.

Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.

Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.


The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International, and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Donna-Bea Tillman", with a stylized flourish at the end.

Donna-Bea Tillman, Ph.D., M.P.A.  
Director  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number: K060487

Device Name: LifeStent FlexStar XL Biliary Stent System

FDA's Statement of the Indications for Use for device:

The LifeStent FlexStar XL Biliary Stent System is indicated for use in the palliation of malignant strictures (neoplasms) in the biliary tree.

Prescription Use X  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Nancy C. Sugdon  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K060487

Page 1 of 1